PO

Insulet Corporation (PODD)

HealthcareMedical Devices
161.14USD
+6.52%
Magic Rank
#1054
Earnings Yield
4.0%
Return on Capital
39.2%
Cap. Boursière
11.6B

Performance vs S&P 500 (5 ans)

PODD.US
S&P 500

À propos Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Analyse Magic Formula

Valeur d'Entreprise11.8B
Marché / Univers
us
USA

"Une entreprise avec un ROC élevé et un EY élevé a statistiquement plus de chances de surperformer le marché."

Indicateurs Clés

P/E Ratio48.14
Rendement dividendeN/A
Dette / Fonds propres0.16
Marge Brute18.7%